Urofollitropin PCD Pharma Franchise Company
Cafoli Lifecare is a Urofollitropin PCD pharma franchise company offering 2 Urofollitropin formulations manufactured at WHO-GMP certified facilities. This is a specialist injectable fertility range, available to franchise partners under exclusive monopoly rights. Urofollitropin is a prescription-only medicine and is supplied strictly to partners holding a valid Drug License, for use under specialist medical supervision.
What is Urofollitropin?
Urofollitropin is a purified preparation of human follicle-stimulating hormone (FSH) obtained from the urine of post-menopausal women. As an FSH preparation it acts directly on the granulosa cells of the ovary to stimulate the growth and maturation of ovarian follicles, and in men it supports spermatogenesis. It is used in assisted reproduction under close clinical monitoring, since ovarian response must be tracked to manage the risk of ovarian hyperstimulation syndrome and multiple pregnancy. Further prescribing background is available from MedlinePlus.
Dosage Forms Available
The Cafoli Lifecare Urofollitropin range is available as Injection across 2 SKUs. As a gonadotropin preparation it requires appropriate cold-chain storage and handling throughout distribution.
Therapeutic Applications
Urofollitropin is used for controlled ovarian stimulation in assisted reproductive technology cycles such as IVF, for ovulation induction in women with anovulatory infertility including those who have not responded to clomifene, and in selected cases of male hypogonadotropic hypogonadism to support spermatogenesis. All use is within specialist, monitored treatment protocols.
Prescribers are reproductive endocrinologists, IVF and fertility specialists, and gynaecologists managing infertility. It is not a general-practice or retail-counter product.
Why Urofollitropin is a High-Potential Molecule for Distributors
Infertility treatment is one of the fastest-growing specialist segments in Indian healthcare, driven by rising awareness, later age at first conception and a rapid expansion of private IVF centres into tier-2 and tier-3 cities. Urofollitropin is a core input into that treatment pathway.
The commercial profile is the opposite of a mass-market molecule, and that is its appeal. Volumes are modest, but value per unit is high, purchasing is institutional and concentrated in a small number of identifiable fertility centres per city, and consumption within a stimulation cycle is predictable. A partner with an existing gynaecology or fertility call list can add this range without expanding the field team. The cold-chain requirement and specialist call list also act as a natural barrier to entry, which protects a monopoly territory in a way that a retail commodity molecule never does. This range suits partners with the infrastructure to handle it, rather than being a general-purpose addition.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers exclusive monopoly rights by district, WHO-GMP certified manufacturing and DCGI-approved formulations. Partners receive full promotional inputs — visual aids, MR bags, samples, prescription pads and product literature — plus transparent net rates and dependable dispatch. Cafoli Lifecare supports 1000+ franchise partners across India.
References
- MedlinePlus — Urofollitropin Injection
- PubMed — Urofollitropin in ovarian stimulation
- WHO Model List of Essential Medicines
Our formulations of Urofollitropin find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: